1. Home
  2. GKOS vs SR Comparison

GKOS vs SR Comparison

Compare GKOS & SR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • SR
  • Stock Information
  • Founded
  • GKOS 1998
  • SR 1857
  • Country
  • GKOS United States
  • SR United States
  • Employees
  • GKOS N/A
  • SR N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • SR Oil/Gas Transmission
  • Sector
  • GKOS Health Care
  • SR Utilities
  • Exchange
  • GKOS Nasdaq
  • SR Nasdaq
  • Market Cap
  • GKOS 5.5B
  • SR 4.5B
  • IPO Year
  • GKOS 2015
  • SR N/A
  • Fundamental
  • Price
  • GKOS $100.14
  • SR $72.89
  • Analyst Decision
  • GKOS Strong Buy
  • SR Buy
  • Analyst Count
  • GKOS 13
  • SR 9
  • Target Price
  • GKOS $135.15
  • SR $78.22
  • AVG Volume (30 Days)
  • GKOS 909.8K
  • SR 425.0K
  • Earning Date
  • GKOS 07-30-2025
  • SR 07-30-2025
  • Dividend Yield
  • GKOS N/A
  • SR 4.31%
  • EPS Growth
  • GKOS N/A
  • SR N/A
  • EPS
  • GKOS N/A
  • SR 4.09
  • Revenue
  • GKOS $404,523,000.00
  • SR $2,428,300,000.00
  • Revenue This Year
  • GKOS $27.88
  • SR $1.50
  • Revenue Next Year
  • GKOS $27.60
  • SR $5.13
  • P/E Ratio
  • GKOS N/A
  • SR $17.78
  • Revenue Growth
  • GKOS 23.92
  • SR N/A
  • 52 Week Low
  • GKOS $77.10
  • SR $58.23
  • 52 Week High
  • GKOS $163.71
  • SR $79.81
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 58.49
  • SR 44.78
  • Support Level
  • GKOS $97.54
  • SR $71.28
  • Resistance Level
  • GKOS $102.82
  • SR $73.31
  • Average True Range (ATR)
  • GKOS 3.51
  • SR 1.15
  • MACD
  • GKOS 0.67
  • SR -0.09
  • Stochastic Oscillator
  • GKOS 77.52
  • SR 39.73

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About SR Spire Inc.

Spire Inc is a public utility holding company with three reportable business segments: Gas Utility, Gas Marketing and Midstream. The Gas Utility segment includes the regulated operations of Laclede Gas, Alabama Gas Corporation ('Alagasco') changed its name to Spire Alabama Inc. effective September 1, 2017, and Laclede Gas Company changed its name to Spire Missouri Inc. effective August 30, 2017. The Gas Utility segment generates a majority of the company's revenue but is subject to seasonal fluctuations. The Gas Marketing segment includes Laclede Energy Resources, Inc, whose operations include the marketing of natural gas and related activities on a non-regulated basis and the Midstream segment includes transportation and storage of natural gas. Maximum revenue from residential area.

Share on Social Networks: